News
Hosted on MSN1mon
Moleculin biotech highlights pivotal Phase 3 trials for Annamycin in AML with interim results expected in 2025Walter Klemp, Chairman and CEO, announced significant progress on the MIRACLE Phase 3 pivotal trial for Annamycin, targeting second-line treatment ... quarterly cash burn to increase to $7-8 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback